Anaptys Announces Participation in November and December Investor Conferences
Rhea-AI Summary
AnaptysBio (ANAB) has announced its participation in four major healthcare investor conferences during November and December 2024. The company's president and CEO Daniel Faga, along with senior management, will participate in fireside chats and one-on-one investor meetings at Guggenheim's Healthcare Innovation Conference (Nov. 13), Stifel Healthcare Conference (Nov. 19), Piper Sandler Healthcare Conference (Dec. 3), and Evercore HealthCONx Conference (Dec. 4). Live webcasts will be available on the company's investor website with replays accessible for 30 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANAB gained 11.72%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Nov. 13, 2024 at 1:30pm ET / 10:30am PT
Stifel 2024 Healthcare Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Nov. 19, 2024 at 1:50pm ET / 10:50am PT
Piper Sandler 36th Annual Healthcare Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Dec. 3, 2024 at 2:30pm ET / 11:30am PT
7th Annual Evercore HealthCONx Conference, Coral Gables, FL
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Dec. 4, 2024 at 1:45pm ET / 10:45am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes two programs targeting co-inhibitory receptors: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other antibodies in its portfolio, including ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the Guggenheim Healthcare Innovation Conference 2024?
How long will the webcasts of AnaptysBio's (ANAB) investor conference presentations be available?
Which investor conferences will AnaptysBio (ANAB) attend in December 2024?
